Listen on the go
  • Listen on the Go
    • Faculty & Disclosures
    Prof. Peter Rossing

    Steno Diabetes Center Copenhagen, Herlev, Denmark

    Prof. Peter Rossing is head of complications research and chief physician at the Steno Diabetes Center Copenhagen, and professor in endocrinology with a focus on diabetic angiopathy at the University of Copenhagen. He leads a team dedicated to the research of micro-and macrovascular complications of diabetes and, since obtaining a specialist degree in internal medicine and endocrinology in 2004, has investigated the pathophysiology of the diabetic kidney at different stages, identifying several key risk markers for the development of diabetic nephropathy. read more

    He has been involved in several intervention studies in patients with overt diabetic nephropathy aiming at improving prognosis. In addition to studies on conventional antihypertensive agents, he has also been involved in some of the first studies of angiotensin II receptor blockers, aldosterone antagonists and, most recently, studies of direct renin inhibition with aliskiren in diabetic kidney disease.

    Prof. Rossing has co-authored over 570 publications and has an h–index of 79. He has received several national and international awards, including The Minkowski Prize from the European Association for the Study of Diabetes (EASD) in 2005, the Ruth Østerby Award from the European Diabetic Nephropathy Study Group in 2013, the EASD Camillo Golgi Prize in 2016, and the European Hormone Medal from the European Society of Endocrinology in 2022.

    Prof. Peter Rossing discloses: Consultancy fees from Astellas, AstraZeneca, Bayer, Boehringer Ingelheim (BI), Eli Lilly and Company, Gilead, Merck Sharp and Dohme (MSD), Novo Nordisk and Sanofi. Grants/research support from AstraZeneca, Bayer and Novo Nordisk.
    Dr Eden Miller

    Diabetes and Obesity Care, Bend, Oregon, USA

    Dr Eden Miller, an Osteopathic Board-certified family practitioner, received her medical degree from Kirksville College of Osteopathic Medicine in 1997. She completed her residency in family practice at Eastmoreland Hospital in Portland, Oregon and recently completed her certification in obesity management. She is the founder of Diabetes Nation, a nonprofit organization, and CEO of Diabetes and Obesity Care in Bend, Oregon, where she currently practices. read more

    Dr Miller cultivated a special interest in diabetes after contracting type 1 diabetes while in medical school and, from that personal experience, her practice has extended to subspecialize in diabetes care.

    An impassioned speaker, Dr Miller has given more than 1,250 lectures in the field of diabetes to healthcare professionals and patients alike, on subjects such as diabetes management, continuous glucose monitoring technology, insulin pump therapy, obesity and metabolism intervention, clinical research, and healthcare policy. Her adage for care is that “I only succeed as a provider if I turn patients into experts on their own disease.”

    Dr Miller believes that a physiologic, patient-individualized approach to diabetes intervention is crucial to success and that there needs to be a “collaborative effort” where patients are “unhindered by fear of personal scrutiny” and that “barriers for effective treatment need to be removed.”

    Dr Eden Miller discloses: Advisory board/panel fees from Abbott, Bayer, Eli Lilly and Company, and Novo Nordisk. Grants/research support from Abbott. Speaker’s bureau fees from Abbott, Bayer, Boehringer Ingelheim (BI), Eli Lilly and Company, and Novo Nordisk.
    Downloads

    View and download resources from this activity to support your learning and share with colleagues

    Download Slides
    Download Slides
    Download Slides
    Download Slides
    CORRECT!
    Next question
    touchCARDIO touchCARDIO
    • FILTER YOUR SEARCH
    Content Type:
    Speciality:
    More Specialities
    Conference:

    • Myocardial Infarction

    An Introduction to Myocardial Infarction

    Acute myocardial infarction (MI) is one of the leading causes of death in the developed world, and affects three million people a year. All MIs involve a decrease in coronary blood flow, resulting in necrosis of the heart muscle, and are classified as non-ST-segment elevation MI (NSTEMI) or ST-segment elevation MI (STEMI). Prompt diagnosis by 12-lead electrocardiogram and measurement of troponin are essential. Treatment for STEMI requires immediate reperfusion, most often with percutaneous coronary intervention (PCI), though fibrinolysis can be used if immediate PCI is not available. In stable patients, NSTEMI can be managed with antiplatelet agents. Evolving strategies such as intravascular ultrasound (IVUS)-guided PCI, advances in stent technology, and improved antiplatelet therapy have increased survival.

    Myocardial Infarction Content

    Cardiovascular Risk, Cardiovascular Disease, Heart Failure, Myocardial Infarction, Preventive Cardiology, Stroke
    Watch Time: 38 mins
    touchIN CONVERSATION
    Addressing cardiorenal outcomes in CKD and T2D: What are the key considerations for daily practice?
    CE/CME ACCREDITED Prof. Peter Rossing, Dr Eden Miller Translations available:

    Watch experts in endocrinology and in primary care discuss key considerations for addressing cardiorenal outcomes in patients with CKD/T2D

    Learning objectives
    Learning Objectives
    • Identify the epidemiological and pathophysiological drivers behind the progression of CKD
    • Recognize the specific renal and cardiovascular risks associated with CKD and T2D and the therapies available to address them
    • Apply the latest clinical guidelines to treating patients with CKD and T2D in daily practice
    Myocardial Infarction
    Developed by Touch
    Marie-Sophie de Koning, ACC 2022: GIPS-IV: The Groningen Intervention Study For the Preservation of Cardiac Function With Sodium Thiosulfate After ST-segment Elevation Myocardial Infarction
    Watch Time: 4 mins

    The Groningen Intervention study for the Preservation of cardiac function with STS after STEMI (GIPS-IV) trial is a double-blind, randomized, placebo-controlled, multicenter trial. touchCARDIO speaks with Dr Marie-Sophie de Koning (University of Groningen, Groningen, The Netherlands) to discuss her presentation of the GIPS-IV trial and to highlight the rationale, design, and study findings. Questions: Marie-Sophie […]

    Myocardial Infarction
    Developed by Touch
    César Herrera, ACC 2022: The American College of Cardiology Global Heart Attack Treatment Initiative: Improving STEMI management internationally
    Watch Time: 5 mins

    Data from the American College of Cardiology (ACC) Global Heart Attack Treatment Initiative (GHATI) offers a novel insights into ST segment elevation myocardial infarction (STEMI) care in low-middle income countries. touchCARDIO spoke to Prof César Herrera (Albert Einstein College of Medicine, Bronx, NY, USA) to discuss his presentation at the ACC Annual Meeting 2022 entitled […]

    Myocardial Infarction, Heart Failure
    Roxana Mehran, ESC 2021 – the PARADISE-MI Trial
    Watch Time: 9 mins 52

    Dr Roxana Mehran (Director of Interventional Cardiovascular Research and Clinical Trials, Icahn School of Medicine, Mount Sinai Hospital, New York City, NY, USA) kindly shared her thoughts on the the PARADISE-MI trial (NCT02924727) from from the virtual ESC Congress 2021. Questions What has been the impact of angiotensin receptor-neprilysin inhibitors (ARNIs) on the treatment of […]

    Heart Failure, Myocardial Infarction
    Gilles Montalescot, ESC 2021 – the QUORUM Clinical Study
    Watch Time: 8.03 mins

    Prof. Gilles Montalescot (Professor, Pitié-Salpêtrière Hospital, Paris, France) kindly shared his thoughts on the difficulty of treating heart failure after acute myocardial infarction, the use of firibastat and the QUORUM clinical study (NCT03715998) from the virtual ESC Congress 2021. Questions Why does heart failure after acute myocardial infarction remain so challenging to treat? (0.19) Could […]

    Myocardial Infarction
    Marc A Pfeffer, ACC 2021 – Meeting highlights
    Watch Time: 4 mins

    Prof. Marc A Pfeffer (Distinguished Dzau Professor of Medicine, Harvard Medical School, Boston, MA, US) kindly shared his highlights from Virtual ACC 2021. Speaker disclosures: Marc A Pfeffer has received consulting fees/honorarium from: Novo Nordisk, AstraZeneca Pharmaceuticals, DalCor, GlaxoSmithKline, Sanofi-Aventis, Boehringer Ingelheim-Lilly, Corvidia, Peerbridge, Novartis; Research/research grants from: Novartis; Other financial benefit: Novartis, DalCor Support: Interview […]

    Myocardial Infarction
    Marc A Pfeffer, ACC 2021 – Findings from PARADISE-MI
    Watch Time: 7 mins

    We were delighted to have the opportunity to speak with Prof. Marc A Pfeffer (Distinguished Dzau Professor of Medicine, Harvard Medical School, Boston, MA, US) to discuss the PARADISE-MI trial investigating sacubitril/valsartan vs. ramipril in a contemporary enriched AMI population, presented at ACC 2021. Abstract Title: Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in […]

    Myocardial Infarction
    Comprehensive Review of Complete Versus Culprit-only Revascularization for Multivessel Disease in ST-segment Elevation Myocardial Infarction
    Robin Jacob, Ayaaz K Sachedina, Sachin Kumar

    Heart International. 2021;15(1):54–9 DOI: https://doi.org/10.17925/HI.2021.15.1.54

    Multivessel disease is common amongst patients presenting with ST-segment elevation myocardial infarction (STEMI). Previous studies have shown that up to 40–65% of patients presenting with STEMI have multivessel disease.1 Pooled analyses of STEMI trials from the fibrinolytic and percutaneous coronary intervention (PCI) eras reveal that the presence of obstructive multivessel disease has been associated with […]

    Myocardial Infarction
    Jose Gonzalez-Juanatey, ACC 2021 – Meeting highlights

    We caught up with Jose Gonzalez-Juanatey to discuss his highlights from this year’s meeting. Speaker disclosures: Jose Gonzalez-Juanatey has received research grants from: Boehringer-Ingelheim, Novartis, Bayer, AstraZeneca, and been a speaker or consultant to: Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, Bristol Myers Squibb, Daichii-Sankyo, Ferrer International, Novo Nordisk, Novartis, Pfizer, Sanofi, Servier. Support: Interview and filming supported […]

    Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72